Factors influencing response rates for advanced colorectal cancer chemotherapy

Annals of Oncology

Volumn 7, Issue 9, 1996, Pages 901-906

  Labianca, R ^a   Pancera, G ^a   Luporini, G ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

advanced colorectal cancer; chemotherapy; evaluation criteria; tumor response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADVANCED CANCER; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030463987     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010791     Document Type: Review

References (39)

1. American Society of Clinical Oncology (ASCO). Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996; 14:671-9.
2. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
3. UICC. Clinical Oncology 1987; 112-5.
4. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407-17.
5. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
6. Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-72.
7. Buroker TR, O'Connell MJ, Wieand HS et al. Randomized comparison of two schedules of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14-20.
8. Cunningham D, Zalcberg JR, Rath U et al. Tomudex, (ZD 1694): Results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Can 1995; 31 A: 1945-54.
9. Valsecchi R, Labianca R, Cascinu S et al. High-dose versus low-dose L-leucovorin as a modulator of 5-days 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study. Proc Am Soc Clin Oncol 1995; 14 (Abstr 457).
10. de Gramont A, Bosset JF, Milan C et al. A prospectively randomized trial comparing 5-FU bolus with low-dose FA (FUFOLld) and 5-FU bolus plus continuous infusion with high-dose FA (LV5-FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 1995; 14 (Abstr 455).
11. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin Oncol 1995; 13: 1303-11.
12. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-53.
13. Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alpha-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17(Suppl 1): 16-21.
14. Pazdur R, Ajani JA, Patt YZ et al. Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990; 8: 2027-31.
15. Kemeny N, Younes A, Seiter K et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma: Assessment of activity and toxicity. Cancer 1990; 66: 2470-5.
16. Wadler S, Lembersky B, Atkins M et al. Phase II trial of fluorouracil and recombinant interferon alpha-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1991; 9: 1806-10.
17. Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alpha-2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297-302.
18. Kohne CH, Wilke H, Hecker H et al. Interferon alpha does not improve the antineoplastic efficacy of high-dose infusional 5-FU plus FA in advanced colorectal cancer. Ann Oncol 1995; 6: 461-6.
19. Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alpha-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995; 13: 921-8.
20. Lokich JJ, Ahlgren JD et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32.
21. Tonkin K, Tritchler D, Tannock I. Criteria of tumor response used in clinical trials of chemotherapy. J Clin Oncol 1985; 3: 870-5.
22. Balducci L, Mowrey K, Parker M. Pharmacology of antineoplastic agents in older patients. In Balducci L, Lyman GH, Ershler VB (eds): Geriatric Oncology. Philadelphia: Lippincott 1992; 165-80.
23. Graf W, Glimelius B, Pahlman L et al. Determinants of prognosis in advanced colorectal cancer. Eur J Can 1991; 9: 1119-23.
24. Niederhuber JE, Ensminger WD. Treatment of metastatic cancer to the liver. In De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott 1993; 2201-25.
25. Kemeny N, Braun DW. Prognostic factors in advanced colorectal carcinoma. The importance of lactic dehydrogenase, performance status and white blood cells count. Am J Med 1983; 74: 786-94.
26. Gennari L, Doci R, Bozzetti F et al. Proposal for a clinical classification of liver metastases. Tumori 1982; 68:443-9.
27. Petrelli N. It is time to stratify with prognostic factors for hepatic metastases. J Clin Oncol 1995; 9: 2471-2.
28. Kemeny N, Niedzwiecki D, Shurgot B et al. Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 1989; 63: 742-7.
29. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976; 38: 388-94.
30. Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy. Proposal for new criteria of tumor response. J Clin Oncol 1984; 2: 1040-6.
31. Bleiberg H. Measurements of response to chemotherapy using ultrasound in metastatic liver involvement. In Wils J, Bleiberg H (eds): Diagnosis and Treatment of Gastrointestinal Tract Cancer. London: Multiscience 1993; 39-43.
32. Sobrero A, Aschele C, Guglielmi A et al. Schedule selective biochemical modulation of 5-fluorouracil: A phase II study in advanced colorectal cancer. Clin Cancer Res 1995; 1: 955-60.
33. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441-51.
34. Herrmann R. 5-Fluorouracil in colorectal cancer, a never ending story. Ann Oncol 1996; 7: 551-2.
35. Glimelius B, Hoffman K, Graf W. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
36. Wadler S, Schwartz EL. Chemotherapy for colorectal carcinoma: Observations regarding recent clinical trials using biochemical modulation. J Clin Oncol 1995; 9: 2676-7.
37. Michels KB. Quo vadis meta-analysis? A potentially dangerous tool if used without adequate rules. In De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: Lippincott 1992; 243-8.
38. Chalmers TC, Lau J. Meta-analysis of randomized controlled trials applied to cancer therapy. In De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: Lippincott 1992; 235-41.
39. Buyse M, Piedbois P. Meta-analysis, use and misuse. J Clin Oncol 1993; 11: 382.